Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)

NCT07203846 is registered in ClinicalTrials.gov with Collegium Medicum w Bydgoszczy as lead sponsor.

NCT NCT07203846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07203846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)
Lead sponsor
Collegium Medicum w Bydgoszczy
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
June 30, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acs - acute coronary syndrome, anti-bacterial agents, blood platelets, drug effects, drug resistance, dysbiosis, microbiota, myocardial infarction (mi), platelet aggregation, platelet aggregation inhibitors, platelet function tests, rifaximin, ticagrelor